Revenue Recognition - Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 6,165	$ 4,790
Collaborative Revenue
Disaggregation of Revenue [Line Items]
Total revenue	2,750
Collaborative Revenue | CSL Vifor Profit Sharing [Member]
Disaggregation of Revenue [Line Items]
Total revenue	2,750
Collaborative Revenue | CSL Vifor [Member]
Disaggregation of Revenue [Line Items]
Total revenue	2,750	0
Commercial Supply Revenue
Disaggregation of Revenue [Line Items]
Total revenue	3,191	4,790
Commercial Supply Revenue | CSL Vifor [Member]
Disaggregation of Revenue [Line Items]
Total revenue	3,191	4,790
Clinical Compound Revenue
Disaggregation of Revenue [Line Items]
Total revenue	99
Clinical Compound Revenue | Maruishi Pharmaceutical Co., Ltd. [Member]
Disaggregation of Revenue [Line Items]
Total revenue	99	0
Royalty Revenue
Disaggregation of Revenue [Line Items]
Total revenue	125
Royalty Revenue | CSL Vifor Kapruvia [Member]
Disaggregation of Revenue [Line Items]
Total revenue	125
Royalty Revenue | CSL Vifor [Member]
Disaggregation of Revenue [Line Items]
Total revenue		$ 0
Royalty Revenue | CSL Vifor [Member] | CSL Vifor Kapruvia [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 125